Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S8 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
  1. Home
  2. Publications
  3. Supplementary Figure S8 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models

Supplementary Figure S8 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models

Authors:
  • DJDejan Juric
    Dejan Juric
  • KSKyung Song
    Kyung Song
  • RJRadia M. Johnson
    Radia M. Johnson
  • MAMelissa K. Accordino
    Melissa K. Accordino
  • PBPhilippe L. Bedard
    Philippe L. Bedard
  • Andrés Cervantes
    Andrés Cervantes
  • VGValentina Gambardella
    Valentina Gambardella
  • EHErika Hamilton
    Erika Hamilton
  • Antoine Italiano
    Antoine Italiano
  • KKKevin Kalinsky
    Kevin Kalinsky
  • IKIan E. Krop
    Ian E. Krop
  • Mafalda Oliveira
    Mafalda Oliveira

Open Access
Publisher website
Google Scholar
  • 6 January 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.31006720
Abstract
FGFR2 ectopic expression potentiates inavolisib mediated mutant p110α degradation and enhance PI3K activity more than matched control cells
Keywords
  • BREAST CANCER
  • CELL SIGNALING
  • CLINICAL TRIAL RESULTS
  • PHASE I CLINICAL TRIALS
  • DRUG MECHANISMS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.